Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating restated by analysts at Wedbush in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $165.00 target price on the stock. Wedbush‘s target price would indicate a potential upside of 71.49% from the company’s current price.

Several other equities research analysts have also recently commented on ORKA. Piper Sandler reaffirmed an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Mizuho set a $120.00 price target on Oruka Therapeutics in a report on Thursday, September 3rd. BTIG Research reaffirmed a “buy” rating and issued a $151.00 price target on shares of Oruka Therapeutics in a report on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. Finally, UBS Group increased their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $133.00.

Oruka Therapeutics Stock Up 6.5%

Shares of Oruka Therapeutics stock traded up $5.89 during mid-day trading on Tuesday, reaching $96.22. 444,758 shares of the stock traded hands, compared to its average volume of 1,083,533. The business has a 50-day moving average of $89.99 and a 200 day moving average of $67.22. Oruka Therapeutics has a fifty-two week low of $25.23 and a fifty-two week high of $115.51. The stock has a market capitalization of $6.37 billion, a PE ratio of -47.45 and a beta of -0.37.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, equities research analysts expect that Oruka Therapeutics will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 9,999 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $80.60, for a total transaction of $805,919.40. Following the completion of the sale, the senior vice president owned 14,219 shares of the company’s stock, valued at $1,146,051.40. This trade represents a 41.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Klein sold 25,000 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $83.62, for a total value of $2,090,500.00. Following the sale, the chief executive officer directly owned 923,128 shares of the company’s stock, valued at approximately $77,191,963.36. This trade represents a 2.64% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 154,950 shares of company stock valued at $14,102,680 over the last quarter. 23.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new position in shares of Oruka Therapeutics during the second quarter worth $2,874,000. Sei Investments Co. boosted its position in shares of Oruka Therapeutics by 136.0% during the first quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after buying an additional 13,164 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Oruka Therapeutics by 517.1% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 104,310 shares of the company’s stock worth $9,927,000 after buying an additional 87,408 shares during the period. Braidwell LP purchased a new position in shares of Oruka Therapeutics during the second quarter worth $26,473,000. Finally, Palo Alto Investors LP purchased a new position in shares of Oruka Therapeutics during the second quarter worth $3,192,573. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Oruka Therapeutics

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: In the ongoing EVERLAST-B Phase 2b trial, 61% of patients receiving the 600 mg dose achieved complete skin clearance (PASI 100) at Week 16, while 86% achieved at least 90% skin clearance (PASI 90). The results were reportedly highly consistent with the earlier EVERLAST-A study, and Oruka said ORKA-001’s safety and tolerability profile remained favorable. Oruka Announces Positive Week 16 ORKA-001 Results
• Positive Sentiment: The strong efficacy data prompted reports that ORKA-001 could represent a major advance in psoriasis treatment. Guggenheim also estimated the therapy could generate peak sales of approximately $7 billion, adding to the commercial opportunity investors are assigning to the program. Guggenheim Estimates ORKA-001 Peak Sales
• Positive Sentiment: Oruka is targeting Phase 3 initiation for ORKA-001 in the first half of 2027, with 52-week EVERLAST-A results expected in December 2026 and ORKA-002 Phase 2 psoriasis results expected in the first quarter of 2027. These upcoming catalysts may be supporting investor interest. Oruka Clinical Development Update
• Positive Sentiment: Wedbush reaffirmed its “outperform” rating and raised or maintained a $165 price target, implying roughly 74% upside from the cited reference price. Wedbush Oruka Rating
• Neutral Sentiment: Reported short interest was listed at zero shares, producing a zero-day days-to-cover ratio; therefore, short covering does not appear to be a meaningful explanation for the move.
• Negative Sentiment: Recent data also show extensive insider selling and no reported insider purchases over the past six months, a potential cautionary signal for investors despite the favorable trial results.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.